Hogan Lovells acted for CatalYm on €50m Series-C financing round
Hogan Lovells acted for CatalYm on €50m Series-C financing round
Hogan Lovells global law firm advised Bavarian CatalYm GmbH on a €50 million Series-C financing round.
Jointly headed by new investors, Brandon Capital and Jeito Capital, the oversubscribed round ran with the participation from Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion, the existing investors.
CatalYm, the biotechnology company, based in Martinsried, is developing advanced immunotherapies in cancer research. Concerning further clinical development of the lead product, Visugromab, a monoclonal antibody designed, the funding will support to neutralise a specific protein (GDF-15) that tumours use to safe guard themselves from the body's own immune system.
Hogan Lovells provided all-inclusive legal advice to CatalYm in this funding round. On continuing basis, the Life Sciences practice around partner Arne Thiermann has been supporting CatalYm.
The transaction was headed by Munich partner Nikolas Zirngibl and senior associate Thiemo Woertge and the team comprised of Dr. Kilian Pfahl (Associate), (all Corporate/ Venture Capital, Munich); Arne Thiermann (Partner, Hamburg), Dr. Karolin Hiller (Senior Associate, Berlin) (both Strategic Operations Agreement Regulations/ Life Sciences).
